Navigation Links
Scientists Unravel Mystery of Tamoxifen Resistance
Date:11/12/2008

Some breast tumors produce a protein that defeats the drug

WEDNESDAY, Nov. 12 (HealthDay News) -- As many as 35 percent of women who take tamoxifen to prevent the return of breast cancer do not respond to the drug -- and now scientists think they know why.

A battle between proteins to turn a breast cancer gene off or on determines if tamoxifen works or not, the scientists report. The finding could be used to spot those women who won't respond to the drug, and it may even lead to new therapies.

"Given the fact that tamoxifen is such a commonly prescribed drug for the treatment of breast cancer, understanding how it works and what happens when it fails is critical to making better drugs," Jason Carroll, from the Cancer Research UK Cambridge Research Institute, said during a Tuesday teleconference on the research.

His team published its report in the Nov. 12 online edition of Nature.

Tamoxifen resistance is a significant problem, affecting 25 percent to 35 percent of breast cancer patients, the authors said.

Now, the puzzle of resistance to the drug may be solved.

"For tamoxifen to work, it has to be able to switch off a very powerful cancer gene," Carroll said. Tamoxifen stops tumor growth by binding to the estrogen receptor and blocking the HER-2 gene, which otherwise causes cancer cells to divide. "If this switch fails, cancer cells become tamoxifen-resistant and tamoxifen is no longer effective," Carroll explained.

In the study, Carroll's team found how this gene can be switched on and off.

The switch for the HER2 gene is hidden within the gene, Carroll said. That switch is a signaling molecule called PAX2. "PAX2 is the handle that keeps HER2 switched off," he said.

If PAX2 isn't there -- or is forced out by another protein called AIB-1 -- the switch fails, Carroll said. "It's a tug of war," he said. "It's a competition between PAX2 and AIB-1. The balance between PAX2 and AIB-1 determines whether HER2 is switched on or switched off, and this directly dictates whether tamoxifen works or not."

The researchers found that high levels of PAX 2 were linked to longer survival for women taking tamoxifen, while tougher, tamoxifen-resistant tumors had high levels of AIB1.

This information could be used to predict which patients are likely to respond to tamoxifen, and which patients are not likely to respond to the drug, Carroll said.

"If we can identify the women who are not going to respond to tamoxifen we can think about alternative therapies, which are probably going to be more effective for these women," Carroll said.

Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, believes the finding will not have an immediate effect on treatment, but might help direct therapy in the future.

"We have learned a lot about makes a cancer cell a cancer cell, and how it works," Lichtenfeld said. "And we have also learned how to better treat breast cancer."

"Understanding these mechanisms will inevitably open up new treatment opportunities," Lichtenfeld said.

More information

For more information on breast cancer, visit the American Cancer Society.



SOURCES: Nov. 11, 2008, teleconference with: Jason Carroll, Ph.D., Cancer Research UK Cambridge Research Institute; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; Nov. 12, 2008, Nature, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists Unravel Mystery of Tamoxifen Resistance
(Date:1/23/2017)... Switzerland (PRWEB) , ... January 23, 2017 , ... ... lab and production applications. However, choosing the right method is paramount to success. ... occur more often in situations where multiple persons use the same equipment. Rare ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... providing high-quality general gynecological care and gynecological services for women of ... personalized care for a wide variety of reproductive services from routine health screenings ...
(Date:1/23/2017)... ... 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating and ... Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the third ... a preacher for over nineteen, a pastor for over fifteen years. He is a ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals ... of a simple test will take days to arrive to the end customer, having ... direct access to their lab tests, bypassing the cost and delay of traditional means. ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites ... isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the ... key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are ... BCC Research reveals in its new report that markets in ... see strong growth due to rising government healthcare spending, increased levels of ... Continue Reading ... ...
(Date:1/23/2017)... Spain , January 23, 2017 ... clinical-stage biopharmaceutical company focused on treatments for calcification ... been enrolled in the Phase IIb "CaLIPSO Study" ... treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) ... patients, in the last stage of chronic kidney ...
(Date:1/22/2017)... , Saudi Arabia , January 22, 2017 ... US and UAE discuss ... , at the World Economic Forum   "The management ... by big data and powered by artificial intelligence and this trend is going ... the ,Hospital of the Future, at the concluding day of the 47 th ...
Breaking Medicine Technology: